View Older Stories View More Recent Stories

Jul 10, 2025 02:26AM Goldman Sachs Starts Neurocrine Bio. (NBIX) at Buy
Jul 9, 2025 05:59AM Neurocrine Bio. (NBIX) PT Raised to $174 at UBS
Jul 7, 2025 07:04AM Neurocrine starts phase 1 trial for experimental CAH treatment
Jun 27, 2025 08:31AM Neurocrine Biosciences (NBIX) Presents New Post-Hoc Data Analyses from KINECT-HD Study
Jun 20, 2025 08:31AM Neurocrine Biosciences (NBIX) Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA Capsules in Older Adults with Tardive Dyskinesia
Jun 9, 2025 04:05PM Neurocrine Biosciences (NBIX) Appoints Lewis Choi as Chief Information Officer
Jun 4, 2025 06:16AM Guggenheim Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Jun 2, 2025 06:58AM RBC Capital on Neurocrine Bio. (NBIX): 'We See Room for Additional Share Upside'
May 30, 2025 04:30PM Fate Therapeutics (FATE) names Matthew Abernethy to Board
May 28, 2025 04:07PM Neurocrine Biosciences (NBIX) Presents New Positive Data from Phase 2 Study of NBI-1117568
May 27, 2025 09:45AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
May 16, 2025 08:31AM Neurocrine Biosciences (NBIX) to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
May 16, 2025 08:26AM Neurocrine Biosciences (NBIX) Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
May 6, 2025 10:21AM Neurocrine Bio. (NBIX) PT Raised to $152 at UBS
May 6, 2025 09:55AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
May 6, 2025 09:46AM Neurocrine Bio. (NBIX) PT Raised to $145 at RBC Capital Following 'Surprising Commercial Momentum'
May 6, 2025 09:19AM Neurocrine Bio. (NBIX) PT Raised to $115 at BMO Capital as 'Crenessity Surprises Higher'
May 6, 2025 09:14AM Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
May 6, 2025 08:37AM Neurocrine Bio. (NBIX) PT Lowered to $154 at Piper Sandler
May 6, 2025 07:23AM Neurocrine Bio. (NBIX) PT Raised to $139 at Needham
May 6, 2025 04:28AM Neurocrine Bio. (NBIX) PT Raised to $190 at Evercore ISI
May 5, 2025 04:09PM Neurocrine Biosciences (NBIX) Misses Q1 EPS by 7c
Apr 28, 2025 07:18AM Neurocrine Bio. (NBIX) PT Lowered to $158 at Canaccord Genuity
Apr 23, 2025 10:03AM Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Apr 22, 2025 06:58AM Neurocrine Bio. (NBIX) PT Lowered to $168 at H.C. Wainwright
Apr 15, 2025 07:19AM Needham Upgrades Neurocrine Bio. (NBIX) to Buy
Apr 14, 2025 06:23AM RBC Capital Upgrades Neurocrine Bio. (NBIX) to Outperform
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Apr 11, 2025 09:44AM Piper Sandler: 'What Biotech Names to Own in Market Volatility'
Apr 4, 2025 10:40AM Neurocrine Bio. (NBIX) PT Lowered to $137 at UBS
Apr 4, 2025 08:01AM Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer
Apr 2, 2025 09:07AM Stifel shares update on CAH stocks following conversation with physicians
Mar 20, 2025 08:32AM Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules
Mar 13, 2025 06:58AM Cantor Biotech industry report, buying value in RevGens
Mar 11, 2025 09:19AM Neurocrine Bio. (NBIX) PT Lowered to $139 at RBC Capital
Mar 5, 2025 08:30AM Neurocrine Biosciences (NBIX) Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Feb 21, 2025 08:00AM Neurocrine Biosciences (NBIX) Announces $500M Share Buyback
Feb 11, 2025 04:16AM Deutsche Bank Starts Neurocrine Bio. (NBIX) at Hold
Feb 10, 2025 09:45AM Neurocrine Bio. (NBIX) PT Lowered to $154 at UBS
Feb 10, 2025 07:28AM Neurocrine Bio. (NBIX) PT Lowered to $163 at Guggenheim
Feb 10, 2025 06:39AM Neurocrine Bio. (NBIX) PT Lowered to $185 at H.C. Wainwright
Feb 7, 2025 08:15AM Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
Feb 7, 2025 06:42AM Neurocrine Bio. (NBIX) PT Lowered to $163 at Canaccord Genuity
Feb 7, 2025 06:08AM Neurocrine Bio. (NBIX) PT Lowered to $179 at BofA Securities
Feb 6, 2025 04:13PM Neurocrine Biosciences (NBIX) Tops Q4 EPS by 12c ; Offers Guidance
Jan 28, 2025 07:57AM Neurocrine Bio. (NBIX) PT Maintained at $166 at Stifel
Jan 21, 2025 04:06PM Neurocrine Biosciences (NBIX) Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
Jan 16, 2025 10:01AM Oppenheimer Reiterates Outperform Rating on Neurocrine Bio. (NBIX)
Jan 8, 2025 08:34AM Neurocrine Biosciences (NBIX) Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Jan 8, 2025 07:23AM Piper Sandler Reiterates Overweight Rating on Neurocrine Bio. (NBIX), Highlighting Crenessity's Potential
View More Recent Stories View Older Stories